Similar Search Results

An Application of a Proposed Framework for Formulary Listing in Low-Income Countries: The Case of Côte d'Ivoire

Diaby, Vakaramoko; Lachaine, Jean - In: Applied Health Economics and Health Policy 9 (2011) 6, pp. 389-402

its current drug reimbursement process because of budgetary constraints. One method of achieving this is to implement a … importance in the decision making around drug reimbursement. Second, a set of priority treatments to be assessed was determined …. Once the treatments eligible for reimbursement were determined, scores were assigned to these treatments according to their …

Persistent link: https://www.econbiz.de/10011005062

Consumer Mobility in Social Health Insurance Markets: A Five-Country Comparison

Laske-Aldershof, Trea; Schut, Erik; Beck, Konstantin; … - In: Applied Health Economics and Health Policy 3 (2004) 4, pp. 229-241

During the 1990s, the social health insurance schemes of Germany, the Netherlands, Switzerland, Belgium and Israel were significantly reformed by the introduction of freedom of choice (open enrolment) of health insurer. This was introduced alongside a system of risk adjustment to compensate...

Persistent link: https://www.econbiz.de/10005243058

Modelling the Ability of Risk Adjusters to Reduce Adverse Selection in Managed Care

Stafford, Randall S.; Li, Donglin; Davis, Roger B.; … - In: Applied Health Economics and Health Policy 3 (2004) 2, pp. 107-114

Population-based risk adjustment, as applied to reimbursement in managed care settings, may reduce pressures for …

Persistent link: https://www.econbiz.de/10005243066

Insights from Triangulation of Two Purchase Choice Elicitation Methods to Predict Social Decision Making in Healthcare

Whitty, Jennifer A.; Rundle-Thiele, Sharyn R.; … - In: Applied Health Economics and Health Policy 10 (2012) 2, pp. 113-126

Background:Background: Discrete choice experiments (DCEs) and the Juster scale are accepted methods for the prediction of individual purchase probabilities. Nevertheless, these methods have seldom been applied to a social decision-making context. Abstract: Objective:Objective: To gain an...

Persistent link: https://www.econbiz.de/10009647782

A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing

Persson, Ulf; Svensson, Johanna; Pettersson, Billie - In: Applied Health Economics and Health Policy 10 (2012) 4, pp. 217-225

character of a monopoly system, leading to reimbursement decisions where usage of new medicines is limited to subgroups and not … system. The aim of this article is to suggest a modification to the current reimbursement system in Sweden where payment for …

Persistent link: https://www.econbiz.de/10010552620

Public and Decision Maker Stated Preferences for Pharmaceutical Subsidy Decisions: A Pilot Study

Whitty, Jennifer A.; Scuffham, Paul A.; Rundle-Thiele, … - In: Applied Health Economics and Health Policy 9 (2011) 2, pp. 73-79

Background: Consideration of public preferences is desirable when making decisions on the subsidy of pharmaceuticals. Little is known about the preferences of the public for pharmaceutical funding decisions, and no study has directly compared the preferences of members of a pharmaceutical...

Persistent link: https://www.econbiz.de/10010614261

Healthcare Payment Incentives: A Comparative Analysis of Reforms in Taiwan, South Korea and China

Eggleston, Karen; Hsieh, Chee-Ruey - In: Applied Health Economics and Health Policy 3 (2004) 1, pp. 47-56

Payment incentives to both consumers and providers have significant consequences for the equity and efficiency of a healthcare system, and have recently come to the fore in health policy reforms. This review first discusses the economic rationale for the apparent international convergence toward...

Persistent link: https://www.econbiz.de/10005448949

Centralising Drug Review to Improve Coverage Decisions: Economic Lessons From (and For) Canada

Morgan, Steve; McMahon, Meghan; Mitton, Craig - In: Applied Health Economics and Health Policy 5 (2006) 2, pp. 67-73

Drug coverage decisions require information about clinically relevant benefits and risks, as well as economic information about direct and indirect costs, in comparison with relevant treatment alternatives. A recent Canadian initiative aims to improve the evidentiary basis for drug coverage...

Persistent link: https://www.econbiz.de/10005448962

How Much Might Universal Health Insurance Reduce Socioeconomic Disparities in Health?: A Comparison of the US and Canada

Decker, Sandra L.; Remler, Dahlia K. - In: Applied Health Economics and Health Policy 3 (2004) 4, pp. 205-216

A strong association between lower socioeconomic status and worse health has been documented within many countries, but little work has been done to compare the strength of this relationship across countries. We compare the strength of the relationship between income and self-reported health in...

Persistent link: https://www.econbiz.de/10005448966

Impact of Cross-Reference Pricing on Pharmaceutical Prices: Manufacturers' Pricing Strategies and Price Regulation

Stargardt, Tom; Schreyogg, Jonas - In: Applied Health Economics and Health Policy 5 (2006) 4, pp. 235-247

Objective: Several EU countries are determining reimbursement prices of pharmaceuticals by cross-referencing prices of … direct and indirect impact of a price change depends mainly on the method applied to set reimbursement prices. When applying … cross-reference pricing, the reimbursement price is either determined by the lowest of foreign prices (e.g. Portugal), the …

Persistent link: https://www.econbiz.de/10005404742